Research
2008 Competion
In 2008-2009, the Quebec Breast Cancer Foundation awarded $4 million in research grants to 11 scientific teams dedicated to breast cancer research. Allocated for a three-year period, the grants are intended exclusively for researchers in the Quebec medical research community.
Scientific evaluation process by peers
In May 2008, the Quebec Breast Cancer Foundation and The Cancer Research Society (CRS) jointly launched a competition for awarding the Foundation’s grants in the scientific community of Quebec. By the August 5 deadline, 47 grant applications were submitted.
Following a critical analysis and a two-day deliberation, each of the 47 projects received a score from the experts committee panel, who made their recommendations to the Foundation’s Board of directors. Therefore, according to the budget available, 11 research projects in biology and cancer treatment were selected to receive a total of $4 million over the next three years. These research projects will help, among other things, reveal the genes that prevent the formation of malignant tumors, prevent and control metastases, reduce resistance to certain effective medications, and develop new treatments or combinations of treatments.
For more information on the granting program, click here.
The following research projects were accepted. Summaries of each project can be found in our « Research Programs » sections.
Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal
| Focal adhesion regulators of early invasive breast cancer: Therapeutic targeting in preclinical models and clinical validation in progressive breast cancer | $450,000
| |
Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal | The role of DARPP-32 in resistance to trastuzumab in breast cancer | $381,456
| |
Dr. Jean-François Boileau, MD, M.Sc.
| Centre Hospitalier de l’Université de Montréal, Montréal
| Sentinel node biopsy following neoadjuvant chemotherapy in biopsy proven node positive patients | $424,500
|
McGill University, Montréal
| Hybrid antiestrogen/histone deacetylase inhibitors as new breast cancer therapies | $450,000
| |
Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal
| Characterization of elF2a kinases as novel targets of oncogenic signaling in breast tumorigenesis with therapeutic potential | $306,817 | |
Université de Montréal, Montréal | Genetic determinants of transformation in basal-like breast tumors | $449,937
| |
|
| McGill University, Montréal
| Gene expression and phenotypic characterization of circulating tumor cells: Towards an understanding of the seeds of metastasis | $449,998 |
|
| Research Centre of the Centre Hospitalier de l’Université Laval, Quebec
| In vitro and in vivo evaluation of three molecules of high therapeutic potential with different mechanisms of action in the treatment of ER+/ER- breast cancers | $405,000
|
|
| McGill Cancer Centre, Montréal
| Role of the protein tyrosine phosphatase Prl-2 in breast cancer development and metastasis | $448,337
|
|
| Centre de recherche en cancérologie, CHUQ, Quebec | Identification of protein partners required for YB-1 to confer chemoresistance in breast tumors | $58.500 |
|
| McGill University, Montréal
| Role of the tumor suppressor PTEN (Phosphatase and Tensin homolog deleted on chromosome Ten) in ErbB-2 induced mammary tumorigenesis | $60,500 |
* Originally financed by the Quebec Breast Cancer Foundation (QBCF), this granting program will now be co-financed by the QBCF and Canadian Breast Cancer Research Alliance. The new research amount will be $658 349 over 5 years.
** The Cancer Research Society and the Quebec Breast Cancer Foundation are co-financing this project.
You can find more information on all funded projects since 1994.